Search

Lorlatinib

include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to

Streptococcus pneumoniae type 14 capsular polysaccharide antigen

It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 14 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 14 of *Streptococcus pneumoniae*

Dibenzepin

Dibenzepin is approved for use in Europe.

Indacaterol

It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.

Podophyllin

Podophyllin is the principal active component. Podophyllin arrests mitosis in metaphase. … Podophyllin is a resin extracted from the roots of _Podophyllum peltatum_ (American mandrake) and _Podophyllum emodi_, which contains numerous compounds, amongst which is podophyllin (as well as the drug

Relatlimab

[L41300] Opdualag was subsequently approved in the European Union in July 2022[L49996] and in Canada in September 2023.[L50001] … [A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and has garnered interest in the treatment of a variety of cancers, including leukemia

Vanadium

Bezlotoxumab

[L46976] On November 22, 2016, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization. … [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection.

Mequinol

Mequinol is a phenol used in various applications. … It is found as an active ingredient in topical drugs used for skin depigmentation indicated for the treatment of solar lentigines.

Garadacimab

[L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan. … the signalling cascade that results in angioedema.